Home > Research > Publications & Outputs > An information-theoretic Phase I/II design for ...

Electronic data

  • PhaseI_II_Final_To_Send_arxiv

    Rights statement: This is the peer reviewed version of the following article: Mozgunov, P. and Jaki, T. (2018), An information theoretic phase I–II design for molecularly targeted agents that does not require an assumption of monotonicity. J. R. Stat. Soc. C. . doi:10.1111/rssc.12293 which has been published in final form at http://onlinelibrary.wiley.com/doi/10.1111/rssc.12293 This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.

    Accepted author manuscript, 529 KB, PDF document

    Available under license: CC BY: Creative Commons Attribution 4.0 International License

Links

Text available via DOI:

View graph of relations

An information-theoretic Phase I/II design for molecularly targeted agents that does not require an assumption of monotonicity

Research output: Contribution to journalJournal article

E-pub ahead of print

Standard

An information-theoretic Phase I/II design for molecularly targeted agents that does not require an assumption of monotonicity. / Mozgunov, Pavel; Jaki, Thomas Friedrich.

In: Journal of the Royal Statistical Society: Series C (Applied Statistics), Vol. 68, No. 2, 15.06.2018, p. 347-367.

Research output: Contribution to journalJournal article

Harvard

APA

Vancouver

Author

Mozgunov, Pavel ; Jaki, Thomas Friedrich. / An information-theoretic Phase I/II design for molecularly targeted agents that does not require an assumption of monotonicity. In: Journal of the Royal Statistical Society: Series C (Applied Statistics). 2018 ; Vol. 68, No. 2. pp. 347-367.

Bibtex

@article{45ebbdf610bd4ac6827010e454165a88,
title = "An information-theoretic Phase I/II design for molecularly targeted agents that does not require an assumption of monotonicity",
abstract = "For many years phase I and phase II clinical trials have been conducted separately, but there has been a recent shift to combine these phases. Although a variety of phase I–II model‐based designs for cytotoxic agents have been proposed in the literature, methods for molecularly targeted agents (TAs) are just starting to develop. The main challenge of the TA setting is the unknown dose–efficacy relationship that can have either an increasing, plateau or umbrella shape. To capture these, approaches with more parameters are needed or, alternatively, more orderings are required to account for the uncertainty in the dose–efficacy relationship. As a result, designs for more complex clinical trials, e.g. trials looking at schedules of a combination treatment involving TAs, have not been extensively studied yet. We propose a novel regimen finding design which is based on a derived efficacy–toxicity trade‐off function. Because of its special properties, an accurate regimen selection can be achieved without any parametric or monotonicity assumptions. We illustrate how this design can be applied in the context of a complex combination–schedule clinical trial. We discuss practical and ethical issues such as coherence, delayed and missing efficacy responses, safety and futility constraints.",
keywords = "Combination-schedule studies, dose finding, molecularly targeted agents, Phase I-II clinical trial, trade-off function",
author = "Pavel Mozgunov and Jaki, {Thomas Friedrich}",
note = "This is the peer reviewed version of the following article: Mozgunov, P. and Jaki, T. (2018), An information theoretic phase I–II design for molecularly targeted agents that does not require an assumption of monotonicity. J. R. Stat. Soc. C. . doi:10.1111/rssc.12293 which has been published in final form at http://onlinelibrary.wiley.com/doi/10.1111/rssc.12293 This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.",
year = "2018",
month = jun
day = "15",
doi = "10.1111/rssc.12293",
language = "English",
volume = "68",
pages = "347--367",
journal = "Journal of the Royal Statistical Society: Series C (Applied Statistics)",
issn = "0035-9254",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - An information-theoretic Phase I/II design for molecularly targeted agents that does not require an assumption of monotonicity

AU - Mozgunov, Pavel

AU - Jaki, Thomas Friedrich

N1 - This is the peer reviewed version of the following article: Mozgunov, P. and Jaki, T. (2018), An information theoretic phase I–II design for molecularly targeted agents that does not require an assumption of monotonicity. J. R. Stat. Soc. C. . doi:10.1111/rssc.12293 which has been published in final form at http://onlinelibrary.wiley.com/doi/10.1111/rssc.12293 This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.

PY - 2018/6/15

Y1 - 2018/6/15

N2 - For many years phase I and phase II clinical trials have been conducted separately, but there has been a recent shift to combine these phases. Although a variety of phase I–II model‐based designs for cytotoxic agents have been proposed in the literature, methods for molecularly targeted agents (TAs) are just starting to develop. The main challenge of the TA setting is the unknown dose–efficacy relationship that can have either an increasing, plateau or umbrella shape. To capture these, approaches with more parameters are needed or, alternatively, more orderings are required to account for the uncertainty in the dose–efficacy relationship. As a result, designs for more complex clinical trials, e.g. trials looking at schedules of a combination treatment involving TAs, have not been extensively studied yet. We propose a novel regimen finding design which is based on a derived efficacy–toxicity trade‐off function. Because of its special properties, an accurate regimen selection can be achieved without any parametric or monotonicity assumptions. We illustrate how this design can be applied in the context of a complex combination–schedule clinical trial. We discuss practical and ethical issues such as coherence, delayed and missing efficacy responses, safety and futility constraints.

AB - For many years phase I and phase II clinical trials have been conducted separately, but there has been a recent shift to combine these phases. Although a variety of phase I–II model‐based designs for cytotoxic agents have been proposed in the literature, methods for molecularly targeted agents (TAs) are just starting to develop. The main challenge of the TA setting is the unknown dose–efficacy relationship that can have either an increasing, plateau or umbrella shape. To capture these, approaches with more parameters are needed or, alternatively, more orderings are required to account for the uncertainty in the dose–efficacy relationship. As a result, designs for more complex clinical trials, e.g. trials looking at schedules of a combination treatment involving TAs, have not been extensively studied yet. We propose a novel regimen finding design which is based on a derived efficacy–toxicity trade‐off function. Because of its special properties, an accurate regimen selection can be achieved without any parametric or monotonicity assumptions. We illustrate how this design can be applied in the context of a complex combination–schedule clinical trial. We discuss practical and ethical issues such as coherence, delayed and missing efficacy responses, safety and futility constraints.

KW - Combination-schedule studies

KW - dose finding

KW - molecularly targeted agents

KW - Phase I-II clinical trial

KW - trade-off function

U2 - 10.1111/rssc.12293

DO - 10.1111/rssc.12293

M3 - Journal article

VL - 68

SP - 347

EP - 367

JO - Journal of the Royal Statistical Society: Series C (Applied Statistics)

JF - Journal of the Royal Statistical Society: Series C (Applied Statistics)

SN - 0035-9254

IS - 2

ER -